Gibson Oncology is developing a novel class of proprietary drug candidates currently in clinical trials for the treatment of difficult-to-treat tumors.  Our product candidates are first-in-class based upon dual activity at C-MYC and Topo-1 which will improve safety and efficacy and offer future approaches for treating several cancers.  There are currently five (5) ongoing clinical studies funded by the National Institutes of Health in patients with solid tumors and lymphomas.   Finally, Gibson has developed proprietary second-generation product candidates expanding modes of delivery and treatment approaches in both pediatric and adult populations.